ABSTRACT
We have investigated novel vaccines strategies against severe acute respiratory syndrome (SARS) CoV infection using cDNA constructs encoding the structural antigens; spike (S), membrane (M), envelope (E), or nucleocapsid (N) protein, derived from SARS CoV (strain HKU39849, TW1, or FFM-1). As SARS-CoV is thought to infect the alveolar epithelial cell of the lung,in the present study, a type II alveolar epithelial cell clone, T7, was used to analyze the mechanism of CTL against SARS CoV membrane antigens. Mice vaccinated with SARS CoV (N) DNA or (M) DNA using pcDNA 3.1(+) plasmid vector showed T-cell cells (T7) transfected with SARS (N) or (M) DNA, respectively.
immune responses (CTL induction and proliferation) against type II alveolar epithelial
To determine whether these DNA vaccines could induce T-cell immune responses in humans as well as in mice, SCID-PBL/hu mice were immunized with these DNA vaccines. PBL from healthy human volunteers were administered i.p. into IL-2 receptor -chaindisrupted NOD-SCID mice [IL-2R(-/-) NOD-SCID]. SCID-PBL/hu mice thus constructed can be used to analyze the human immune response in vivo. The SCID-PBL/hu mice were immunized with SARS (N) DNA or (M) DNA and analyzed for a human T-cell immune response. The M DNA vaccine enhanced CTL activity and proliferation in the presence of M peptide in SCID-PBL/hu mice. Furthermore, the SARS N DNA vaccine induced CTL blast cells) and proliferation of spleen cells in SCID-PBL/hu mice. These results, demonstrate that SARS M and N DNA vaccines induced human CTL and human T-cell proliferative responses.
On the other hand, we have developed SARS DNA vaccines that induce human neutralizing antibodies and human monoclonal antibodies against SARS CoV. Transgenic mice expressing SARS-CoV receptor (angiotensin converting enzyme 2) are also under development. These vaccines are expected to induce immune responses specific for SARS CoV in human and should provide useful tool for development of protective vaccines.
INTRODUCTION
The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of corona virus, SARS corona virus (SARS-CoV) more than 8400 patients in about 7 months in over 30 countries and caused more than 800 deaths. The deadly epidemic has had significant impacts on many health, social, economic and political aspects. SARS may resurge in the near future. However, no SARS vaccine is currently available for clinical use. Therefore, we have developed novel vaccine candidates against SARS CoV using cDNA constructs encoding the structural antigens; S, M, E, or N protein. In immunized mice, neutralizing antibodies against the virus and T-cell immunity against virus-infected-cells were studied, since these responses play important roles in protection against many virus infections. In particular, CD8 + CTL plays an important role in T cell immunity against virus infections and in the eradication of murine and human cancers. 4, 5 In the present study, a type II alveolar epithelial cell clone, T7, was used for activity (IFN-γ production by recombinant N protein or N protein-pulsed autologous B γ 1,2,3 . SARS has infected
RESULTS

Induction of CTL against SARS CoV by SARS (N) DNA and SARS (M) DNA vaccine:
Spleen cells from C57BL/6 mice immunized with SARS-S, -M, -N or -E DNA vaccine were cultured with syngeneic T7 lung cells transfected with S, M, N, or E cDNA. 
Augmentation of lymphocyte proliferation specific for SARS CoV antigens by
analyzing precise mechanism of CTL against SARS-CoV membrane antigens, as the SARS-CoV infects alveolar epithelial cell in the lungs. 6 Furthermore, the SCID-PBL/hu model, which is capable of analyzing in vivo human immune response, was also used because it is a more relevant translational model for human cases. 4 These vaccines induce human immune responses (neutralizing antibody and CTL) specific for SARS CoV in human and should provide useful tool for development of protective vaccines.
MATERIALS AND METHODS
Three SARS CoV strains HKU39849 1 , TW-1, and FFM-1 2 and their cDNAs were used. S, M, N, or E cDNA was transferred into pcDNA 3.1(+) vector and pcDNA 3.1(+)/vs-His Topo (QIAGEN K K, Tokyo, Japan). These genes were expressed in eukaryotic cells and Escherichia coli. pcDAN 3.1(+) vector, 50 μg each, containing SARS S, M, N, or E DNA was injected i.m. (M. tibia anterior) into C57BL/6 mice (female, 8 weeks, CLEA Japan Inc, Japan) and BALB/c mice (female, 8 weeks) three times, at an interval of 7 days. Neutralizing antibodies against SARS CoV in the serum from the mice immunized with SARS S, M, N, or E DNA vaccines were assayed using Vero-E6 cell. CTL activity against SARS-CoV was studied using human type II alveolar epithelial cells, T7, expressing SARS antigens. 6 PBL from healthy human volunteers were administered i.p. SCID-PBL/hu mice were constructed. 4 SARS DNA vaccines at 50 μg were injected i.m. into the SCID-PBL/hu mice. CTL activity of human CD8-positive lymphocytes in the spleen from SCID-PBL/hu was assessed using IFN-γ production and 51 Cr-release assay 4, 5 Human monoclonal antibodies were produced from B cell hybridoma using P3U1 myeloma cell and spleen cells from human immunoglobulin transchromosomic mice (KM mice). DNA and SARS M DNA vaccines capable of inducing human neutralizing antibodies against SARS CoV have been established by our SCID-PBL/hu model. It has been demonstrated that angiotensin-converting enzyme 2 (ACE2) is a functional receptor for the SARS CoV. 9 A transgenic mouse with human ACE-2 may be useful as an animal model of SARS. Furthermore, ACE-2 transgenic SCID mice should be useful as a human model for preclinical trial for SARS vaccines, for analyzing human immune responses against SARS infection in vivo. The effect of combination immunization with such SARS vaccines and nentralizing antibody-inducing DNA vaccines is now being studied. These DNA vaccines should provide a useful tool for development of protective vaccines.
SARS M DNA and N DNA vaccines induced human T-cell immune responses (CTL and proliferation) and the production of neutralizing antibodies against SARS-CoV in
